Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling
Summary
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it is supporting the drug development program for a lifesaving countermeasure to acute radiation syndrome (ARS) in a partnership with a global pharmaceutical company. Brett Howell, President of DSS, noted, “This is a perfect application of QSP – translation of mechanisms of action from animal to man. Jill Fiedler-Kelly, President of Cognigen, added, “The scientific team at Cognigen looks forward to assisting in the development of a comprehensive translational modeling and simulation strategy to support dose selection for this important lifesaving treatment.” Shawn O’Connor, chief executive officer of Simulations Plus, added: “We are pleased to have been engaged by industry to support this critical development effort. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.